查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2024881

單純皰疹病毒治療市場規模、佔有率、趨勢和預測：按類型、藥物類型、給藥途徑、分銷管道和地區分類，2026-2034年

Herpes Simplex Virus Treatment Market Size, Share, Trends and Forecast by Type, Drug Type, Route of Administration, Distribution Channel, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 145 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球單純皰疹病毒（HSV）治療市場規模為28億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到42億美元，2026年至2034年的複合年成長率（CAGR）為4.33%。目前，北美市場佔據主導。消費者對各種HSV治療方案的認知度不斷提高、醫療保健支出持續成長以及線上和線下藥局HSV治療方案的廣泛普及是推動市場成長的主要因素。

全球單純皰疹病毒 (HSV) 治療市場正受到 HSV 感染率上升、人們性行為感染(STI) 的認知不斷提高以及抗病毒療法進步的推動。根據世界衛生組織 (WHO) 統計，全球約有 38 億 50 歲以下人群（佔 64%）感染了 1 型單純皰疹病毒 (HSV-1)，這是口唇皰疹的主要病因；另有 5.2 億 15 至 49 歲人群（佔 13%）感染了 2 型單純皰疹病毒 (HSV-2)，這是主要的生殖器皰疹。此外，診斷工具的改進和對早期檢測的日益重視也進一步推動了對有效治療方法的需求。同時，各國政府為提高公眾對性行為感染感染 (STI) 的認知而採取的舉措以及對研發的投入，也在單純皰疹病毒 (HSV) 治療市場的成長中發揮著至關重要的作用。此外，公共和私人部門對創新治療方法（包括疫苗和外用藥物）研發的投資大幅增加，正在推動市場成長。以病人為中心的醫療模式的轉變以及發展中地區醫療基礎設施的擴建，也提振了市場前景。

美國作為主要區域市場脫穎而出，這主要是由於單純皰疹病毒（HSV）相關併發症（例如新生兒皰疹和生殖器皰疹爆發）的負擔日益加重，這些併發症需要先進的醫療干預。這促使人們透過採用聯合治療和個人化醫療來改善治療效果，從而進一步推動市場成長。此外，製藥公司對標靶抗病毒療法的研發投入巨大，也拓展了治療選擇。 2024年11月19日，NOWDiagnostics公司宣布推出其突破性的非處方梅毒檢測檢測套組 ”，該試劑盒已獲得美國食品藥物管理局（FDA）的核准。這款自測檢測套組只需少量血液樣本，15分鐘即可出結果，為檢測性行為感染感染提供了一種私密便捷的方式。該試劑盒可在網路上和全國各地的藥局購買，為個人健康管理提供了一種私密可靠的選擇。此外，藥物輸送系統（包括奈米技術解決方案）的持續技術創新，也使治療更加有效和便利。同時，美國大型生物製藥公司的存在以及完善的醫療保健體系，正在支持創新產品的快速傳播，並提高單純皰疹病毒 (HSV) 治療在美國的市場佔有率。

單純皰疹病毒治療市場的發展趨勢：

口服抗病毒藥物需求不斷成長

根據美國疾病管制與預防中心（CDC）的數據，口服抗病毒藥物，例如阿昔洛韋和伐昔洛韋，預計仍將是治療方法單純皰疹病毒（HSV）感染疾病，特別是復發性生殖器皰疹的一線療法。口服抗病毒療法已將HSV感染率降低了70%至80%。預計到2024年，全球15至49歲人口中約有16%將感染HSV-2，因此對有效口服療法的需求日益成長。隨著人們越來越關注降低感染率和改善患者預後，對口服抗病毒藥物的需求持續成長。隨著HSV在全球範圍內的持續傳播，對治療該感染疾病的需求也將相應增加，因為這些是目前最可靠的治療方法。

廣泛使用局部抗病毒治療

局部抗病毒藥物，例如乳膏和軟膏，是治療復發性單純皰疹病毒（HSV）感染最常用的方法。據美國疾病管制與預防中心（CDC）稱，如果在感染早期使用局部治療藥物，包括二十二醇等藥物，患者的症狀持續時間可能會縮短1-2天。 CDC估計，到2023年，超過50%的HSV患者會傾向於選擇局部治療，因為其使用方便，可以直接塗抹於患處。使用方便和快速緩解症狀是這些治療方法日益普及的原因。此外，建議將局部抗病毒藥物作為口服藥物的輔助性治療，用於控制局部病變。

單純皰疹病毒疫苗的研發

單純皰疹病毒疫苗的研發工作正在穩步推進，美國國立衛生研究院 (NIH) 致力於降低單純皰疹病毒的感染率。截至 2024 年，NIH 資助了多項臨床研究，以評估 HSV 疫苗的有效性。據估計，全球 HSV-2 感染病例超過 5 億例。因此，亟需制定預防措施。 NIH 和其他機構的臨床研究表明，有效的疫苗可以顯著降低 HSV 的感染率，並減少感染者的長期治療費用。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球單純皰疹病毒治療市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依類型

  • 單純皰疹病毒第一型感染疾病
  • 單純皰疹病毒第二型感染疾病
  • 其他

第7章 市場區隔：依藥物類型分類

  • 阿昔洛韋
  • 伐昔洛韋
  • 泛昔洛韋
  • 其他

第8章 市場區隔：依給藥途徑

  • 口服
  • 注射藥物
  • 外用

第9章 市場區隔：依分銷通路分類

  • 醫院藥房
  • 藥局
  • 零售店
  • 網路藥房

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Agenus Inc.
    • Apotex Inc.
    • Avet Pharmaceuticals Inc.
    • Carlsbad Tech
    • EPI Health LLC
    • F. Hoffmann-La Roche Ltd
    • Fresenius SE & Co. KGaA
    • GlaxoSmithKline plc
    • Glenmark Pharmaceuticals Limited
    • Merck & Co. Inc.
    • Novartis AG
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
Product Code: SR112026A5257

The global herpes simplex virus treatment market size was valued at USD 2.8 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 4.2 Billion by 2034, exhibiting a CAGR of 4.33% during 2026-2034. North America currently dominates the market. The growing awareness among individuals about various medications of HSV, increasing healthcare expenditure, and wide availability of HSV medications through online and offline pharmacy stores represent some of the key factors driving the market.

The global herpes simplex virus (HSV) treatment market is driven by a rising prevalence of HSV infections, increased awareness of sexually transmitted infections (STIs), and advancements in antiviral therapies. According to World Health Organization (WHO), about 3.8 billion individuals under the age of 50 (64%) worldwide are infected with herpes simplex virus type 1 (HSV-1), which is the main cause of oral herpes, and 520 million aged 15-49 (13%) are infected with herpes simplex virus type 2 (HSV-2), which is the main cause of genital herpes. Besides this, the growing demand for effective treatment options is further propelled by the availability of improved diagnostic tools and a stronger emphasis on early disease detection. Along with this, government initiatives promoting STI awareness and funding for research and development also play a crucial role in herpes simplex virus (HSV) treatment market growth. Additionally, considerable rise in public and private investments to develop innovative treatment methods, including vaccines and topical medications, is enhancing market growth. A shifting focus toward patient-centric care and expanding healthcare infrastructure in developing regions is creating a positive market outlook.

The United States stands out as a key regional market, primarily driven by an increasing burden of HSV-related complications, including neonatal herpes and genital herpes outbreaks, which demand advanced medical interventions. In line with this, the growing adoption of combination therapies and personalized medicine is enhancing treatment outcomes, further driving the market growth. Additionally, substantial investments by pharmaceutical companies in research and development (R&D) for targeted antiviral therapies is also expanding treatment options. On 19 th November 2024, NOWDiagnostics, Inc., announced the release of the First To Know Syphilis Test, a novel FDA-authorized over-the-counter syphilis test in the U.S. With results as fast as 15 minutes based on a small blood drop, this elf-administered kit provides a confidential and convenient method for detecting sexually transmitted infections. It is available both online and at pharmacies nationwide, offering individuals a private and reliable alternative for managing their health. Moreover, continual technological advancements in drug delivery systems, such as nanotechnology-based solutions, are making treatments more effective and accessible. Concurrently, the presence of leading biopharmaceutical firms and a well-established healthcare system in the U.S. supports the rapid adoption of innovative products, bolstering the US herpes simplex virus (HSV) treatment market share.

HERPES SIMPLEX VIRUS TREATMENT MARKET TRENDS:

Increasing Demand for Oral Antiviral Drugs

According to the U.S. Centers for Disease Control and Prevention (CDC), these drugs, such as oral antiviral drugs: Acyclovir and Valacyclovir, will remain the first-line treatments against HSV infections, especially recurrent cases of genital herpes. Oral antiviral therapies have cut HSV transmission rates by 70 to 80%. In 2024, close to 16% of the world's population aged between 15 and 49 years will be infected with HSV-2, thus creating a need for effective oral treatments. The more emphasis on declining transmission rates and better results for patients enhances the continued need for oral antiviral drugs. As HSV continues to multiply globally, so will the treatment demand for the same infections since they are the most reliable way of managing the condition.

Growing Use of Topical Antiviral Treatments

Topical antiviral preparations, such as topical creams and ointments, are employed for treating HSV recurrences in most cases. The CDC indicates that patients with topical treatments, which include medicines including Docosanol, experience an outbreak that could be shortened by 1 to 2 days if applied early in the course of an infection. According to the CDC, by 2023, over 50% of patients with HSV preferred topical treatment because it is easy and can be applied directly to the affected area. Ease of use and fast relief are factors that support the increasing popularity of these treatments. Furthermore, topical antivirals are recommended as adjunctive therapies to oral drugs to manage localized lesions.

Development of Vaccines for Herpes Simplex Virus

The development of herpes simplex virus vaccine is being researched, and the National Institutes of Health (NIH) are pushing to lower the rate of infections that are caused by herpes simplex virus. As of 2024, NIH have been funding several clinical studies that evaluate the efficacy of HSV vaccines. The global prevalence of HSV-2 infections is estimated at over 500 million cases. Thus, the urgent need for prevention solutions is important. Clinical studies by the NIH and other institutions have shown that an effective vaccine could significantly reduce the rates of HSV transmission and long-term treatment costs for those infected with the virus.

HERPES SIMPLEX VIRUS TREATMENT INDUSTRY SEGMENTATION:

Analysis by Type:

  • Herpes Simples Virus-1 Infection
  • Herpes Simplex Virus-2 Infection
  • Others

Herpes Simplex Virus-1 (HSV-1) primarily causes oral herpes, characterized by cold sores around the mouth and face. The HSV-1 treatment market is driven by increasing awareness, improved diagnostic tools, and innovative antiviral therapies. Current treatment options include over-the-counter medications, prescription antiviral drugs such as acyclovir, and emerging topical treatments. Research into vaccine development and novel therapeutic strategies is further enhancing the potential for effective management of HSV-1 infections.

Herpes Simplex Virus-2 (HSV-2) mainly causes genital herpes, which is a lifetime disease with the episodic attacks. The focus of the treatment market for HSV-2 revolves around antiviral drugs like valacyclovir and famciclovir that suppress the activity of viruses and reduce its transmission. Greater public health interventions and education efforts have reduced stigma while promoting earlier diagnosis and treatment. Drug innovation and vaccine development will further improve the range of options for treating HSV-2 infections.

Analysis by Drug Type:

  • Acyclovir
  • Valacyclovir
  • Famciclovir
  • Others

Acyclovir leads the market in 2025 due to its proven efficacy, widespread availability, and affordability. As one of the first antiviral drugs developed specifically for herpes infections, acyclovir effectively manages outbreaks of both HSV-1 and HSV-2 by inhibiting viral replication. Its oral, topical, and intravenous formulations provide versatility, catering to various patient needs and severity levels. The drug's established safety profile and minimal side effects further contribute to its dominance in the market. Additionally, generic versions of acyclovir ensure accessibility, particularly in cost-sensitive markets. With ongoing advancements in drug formulations, acyclovir continues to set the benchmark for effective antiviral therapies, reinforcing its stronghold in this competitive sector.

Analysis by Route of Administration:

  • Oral
  • Injectable
  • Topical

Oral leads the market in 2025 due to its convenience, efficacy, and widespread patient preference. Oral antiviral medications, such as acyclovir, valacyclovir, and famciclovir, provide effective systemic relief from both HSV-1 and HSV-2 infections, making them a cornerstone of treatment. This route simplifies dosing, enhancing patient compliance and accessibility compared to topical or intravenous alternatives. Oral formulations are particularly favored for managing recurrent outbreaks and for long-term suppressive therapy, offering sustained viral suppression and reduced transmission risk. With advancements in formulation technology, such as extended-release tablets, the oral route continues to strengthen its position as the most practical and widely used method for managing herpes simplex virus infections globally.

Analysis by Distribution Channel:

  • Hospital Pharmacy
  • Drug Stores
  • Retail Stores
  • Online Pharmacy

Hospital pharmacy leads the market in 2025 due to their pivotal role in providing access to prescription antiviral medications. These facilities ensure the availability of critical treatments including acyclovir and valacyclovir for acute and severe infections, often requiring immediate attention. Hospital pharmacies are integral to managing inpatient care, especially for intravenous drug formulations used in complex cases. Their stringent quality control measures, reliable supply chains, and expert pharmaceutical guidance enhance trust and patient outcomes. Additionally, they cater to a diverse patient demographic, from emergency cases to those requiring suppressive therapy. As healthcare infrastructure improves globally, hospital pharmacies continue to dominate as a trusted and indispensable distribution channel in the antiviral treatment market.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share, driven by advanced healthcare infrastructure, high awareness levels, and significant healthcare expenditure. The region's well-established pharmaceutical sector is at the forefront of developing and distributing HSV treatments, which include antiviral medications and topical ointments. Additionally, North America benefits from a strong regulatory framework and widespread access to healthcare, facilitating prompt diagnosis and treatment. The growing prevalence of HSV infections, coupled with an aging population and the increased focus on sexually transmitted diseases (STDs), further enhances the demand for effective treatment options. This market dominance is expected to continue as research and innovation in antiviral therapies advance.

KEY REGIONAL TAKEAWAYS:

UNITED STATES HERPES SIMPLEX VIRUS TREATMENT MARKET ANALYSIS

The U.S. herpes simplex virus (HSV) treatment market is growing steadily and is based on increasing knowledge of the virus and the need to have appropriate management solutions for it. According to the CDC (Center for Disease Control and Prevention), nearly 1 in 6 people aged 14-49 years was affected by genital herpes during 2023, thus there being a steady demand for antiviral treatments. The market reaps the benefit of a sound health care infrastructure and high levels of treatment adherence, including prescription antiviral drugs such as acyclovir as well as the over-the-counter varieties. High adoption levels of telemedicine and electronic prescriptions have streamlined access to treatments. Large players in the market are improving product lines by introducing new forms and combinations to enhance adherence among patients. The market is also progressing in terms of technology by the development of long-acting injectable therapies to offer more comfortable treatment choices.

EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET ANALYSIS

Rising prevalence rates and supportive health initiatives for the treatment of HSV in the European market have increased growth. A study states that close to 12% of Europe's adult population has chronic infection by HSV-2. The demand for antiviral therapies is constantly driven through such prevalence, while both oral and topical medicines remain highly prescribed with health systems emphasizing the better provision for these treatments. The emergence of resistant HSV strains has given birth to the development of new next-generation therapies, including vaccines and long-acting antivirals. The research is actively being carried on by pharmaceutical companies such as Gilead Sciences through clinical trials on innovative treatments. Moreover, public health campaigns reducing stigma and encouraging early diagnosis should improve treatment rates. Further to this, the adoption of digital health platforms for prescription services is further facilitating market growth, making treatments more accessible across the region.

ASIA PACIFIC HERPES SIMPLEX VIRUS TREATMENT MARKET ANALYSIS

This treatment market for HSV in Asia Pacific is rapidly increasing due to higher awareness and increased access to healthcare in developing economies. According to WHO, in the Asia Pacific region, the prevalence of HSV-1 is approximately 50%, though there has been a sudden increase in cases of HSV-2 caused by new sexual behaviors. Antiviral treatments have become more accessible due to increasing adoption of telehealth platforms and e-prescriptions in India and China. Pharmaceutical investment in the region is also creating a market for this area, with companies such as Roche and Abbott expanding their portfolios in antivirals. Innovative treatment options including long-acting injectable antivirals are also gaining traction. Further, growth of healthcare infrastructure and increased disposable income will continue to enhance the growth of the market in the coming years, mainly in Southeast Asia where there is growing demand for effective therapies.

LATIN AMERICA HERPES SIMPLEX VIRUS TREATMENT MARKET ANALYSIS

High infection rates and increased awareness of antiviral therapies drive the Latin American HSV treatment market. According to an industrial report, seroprevalence of herpes simplex virus type 1 in the region is high, with a pooled mean of 83.1%: 57.2% in children, 84.5% in healthy adults, and 90.9% in clinical adults. Such a high prevalence demands effective treatments such as acyclovir and valacyclovir. Public health campaigns target increased availability of antiviral treatments, particularly to underdeveloped communities. Companies such as Teva and Sanofi are improving market presence by localizing the manufacturing and distribution bases. Moreover, increasing disposable income and enhanced healthcare insurance are helping to enhance market performance. Greater awareness of healthy sexuality and protection measures are also augmenting the use of advanced therapies across the region.

MIDDLE EAST AND AFRICA HERPES SIMPLEX VIRUS TREATMENT MARKET ANALYSIS

The Middle East and Africa region is characterized by high infection rates and growing awareness in health care. A study has revealed that 88.8% of the population in Saudi Arabia is infected with HSV-1, mostly contracted before adulthood. The higher prevalence leads to constant demand for antiviral treatments, especially for symptomatic and recurrent cases. Regional governments have been investing in healthcare infrastructures to enhance access to treatment, including oral and topical antivirals. International and local pharmaceutical firms collaborate for the better availability of the effective therapies in the region. Public health campaigns towards educating the population on how to prevent and manage HSV are also contributing to growth in this market. However, it's challenging in rural areas to access health care, which calls for mobile health initiatives and telemedicine solutions.

COMPETITIVE LANDSCAPE:

The competitive landscape of the herpes simplex virus treatment market is influenced by the presence of key pharmaceutical companies focusing on the development and commercialization of innovative antiviral therapies. These companies are heavily investing in research and development to introduce more effective and targeted treatments, aiming to enhance patient outcomes while reducing side effects. Apart from conventional antiviral drugs, gene therapies and immune-modulating drugs are being developed by players. Companies are making strategic partnerships, mergers, and acquisitions in order to broaden product portfolios and expand market reach. Such companies are upgrading their marketing strategies, their distribution networks, and focusing on personalized medicine to address the diverse needs of patients worldwide.

The report provides a comprehensive analysis of the competitive landscape in the herpes simplex virus treatment market with detailed profiles of all major companies, including:

  • Agenus Inc.
  • Apotex Inc.
  • Avet Pharmaceuticals Inc.
  • Carlsbad Tech
  • EPI Health LLC
  • F. Hoffmann-La Roche Ltd
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Merck & Co. Inc.
  • Novartis AG
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Herpes Simplex Virus Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Herpes Simples Virus-1 Infection
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Herpes Simplex Virus-2 Infection
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Acyclovir
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Valacyclovir
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Famciclovir
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectable
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Topical
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacy
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Drug Stores
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Retail Stores
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Online Pharmacy
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Agenus Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Apotex Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 SWOT Analysis
    • 15.3.3 Avet Pharmaceuticals Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Carlsbad Tech
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 EPI Health LLC
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 F. Hoffmann-La Roche Ltd
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
    • 15.3.7 Fresenius SE & Co. KGaA
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 GlaxoSmithKline plc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Glenmark Pharmaceuticals Limited
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Merck & Co. Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Novartis AG
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Sanofi S.A.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Teva Pharmaceutical Industries Ltd.
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis
    • 15.3.14 Viatris Inc.
      • 15.3.14.1 Company Overview
      • 15.3.14.2 Product Portfolio
      • 15.3.14.3 Financials

List of Figures

  • Figure 1: Global: Herpes Simplex Virus Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Herpes Simplex Virus Treatment Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Herpes Simplex Virus Treatment Market: Breakup by Type (in %), 2025
  • Figure 5: Global: Herpes Simplex Virus Treatment Market: Breakup by Drug Type (in %), 2025
  • Figure 6: Global: Herpes Simplex Virus Treatment Market: Breakup by Route of Administration (in %), 2025
  • Figure 7: Global: Herpes Simplex Virus Treatment Market: Breakup by Distribution Channel (in %), 2025
  • Figure 8: Global: Herpes Simplex Virus Treatment Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Herpes Simplex Virus Treatment (Herpes Simples Virus-1 Infection) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Herpes Simplex Virus Treatment (Herpes Simples Virus-1 Infection) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Herpes Simplex Virus Treatment (Herpes Simplex Virus-2 Infection) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Herpes Simplex Virus Treatment (Herpes Simplex Virus-2 Infection) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Herpes Simplex Virus Treatment (Other Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Herpes Simplex Virus Treatment (Other Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Herpes Simplex Virus Treatment (Acyclovir) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Herpes Simplex Virus Treatment (Acyclovir) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Herpes Simplex Virus Treatment (Valacyclovir) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Herpes Simplex Virus Treatment (Valacyclovir) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Herpes Simplex Virus Treatment (Famciclovir) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Herpes Simplex Virus Treatment (Famciclovir) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Herpes Simplex Virus Treatment (Other Drug Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Herpes Simplex Virus Treatment (Other Drug Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Herpes Simplex Virus Treatment (Oral) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Herpes Simplex Virus Treatment (Oral) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Herpes Simplex Virus Treatment (Injectable) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Herpes Simplex Virus Treatment (Injectable) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Herpes Simplex Virus Treatment (Topical) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Herpes Simplex Virus Treatment (Topical) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Herpes Simplex Virus Treatment (Hospital Pharmacy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Herpes Simplex Virus Treatment (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Herpes Simplex Virus Treatment (Drug Stores) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Herpes Simplex Virus Treatment (Drug Stores) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Herpes Simplex Virus Treatment (Retail Stores) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Herpes Simplex Virus Treatment (Retail Stores) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Herpes Simplex Virus Treatment (Online Pharmacy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Herpes Simplex Virus Treatment (Online Pharmacy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: North America: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: North America: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: United States: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: United States: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Canada: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Canada: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Asia-Pacific: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Asia-Pacific: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: China: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: China: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Japan: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Japan: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: India: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: India: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: South Korea: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: South Korea: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Australia: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Australia: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Indonesia: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Indonesia: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Others: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Others: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Europe: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Europe: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Germany: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Germany: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: France: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: France: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: United Kingdom: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: United Kingdom: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Italy: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Italy: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Spain: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Spain: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Russia: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Russia: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Others: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Others: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Latin America: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Latin America: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Brazil: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Brazil: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Mexico: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Mexico: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Others: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Others: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Middle East and Africa: Herpes Simplex Virus Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 84: Middle East and Africa: Herpes Simplex Virus Treatment Market: Breakup by Country (in %), 2025
  • Figure 85: Middle East and Africa: Herpes Simplex Virus Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Global: Herpes Simplex Virus Treatment Industry: SWOT Analysis
  • Figure 87: Global: Herpes Simplex Virus Treatment Industry: Value Chain Analysis
  • Figure 88: Global: Herpes Simplex Virus Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Herpes Simplex Virus Treatment Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Herpes Simplex Virus Treatment Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 3: Global: Herpes Simplex Virus Treatment Market Forecast: Breakup by Drug Type (in Million USD), 2026-2034
  • Table 4: Global: Herpes Simplex Virus Treatment Market Forecast: Breakup by Route of Administration (in Million USD), 2026-2034
  • Table 5: Global: Herpes Simplex Virus Treatment Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 6: Global: Herpes Simplex Virus Treatment Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Herpes Simplex Virus Treatment Market: Competitive Structure
  • Table 8: Global: Herpes Simplex Virus Treatment Market: Key Players